Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Charlotte Roach"'
Autor:
Shanthy Nuti, Yiwei Zhang, Nabila Zerrouki, Charlotte Roach, Gudrun Bänfer, George L Kumar, Edward Manna, Rolf Diezko, Kristopher Kersch, Josef Rüschoff, Bharat Jasani
Publikováno v:
Histopathology. 81:732-741
A common concern among pathologists scoring PD-L1 immunohistochemical staining is interobserver and intraobserver variability. We assessed the interobserver and intraobserver reproducibility of PD-L1 scoring among trained pathologists using a combine
Autor:
Jennifer Robinson, Edward Manna, Charlotte Roach, Ryan Marczak, Arkendra De, Joshua Littrell, Micki Adams
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Chris LaPlaca, Siena Tabuena-Frolli, Karina Kulangara, Jeanette Musser, Lindsay Peltz, Michael A. DiMaio, Rosanne Welcher, Angeliki Apostolaki, Charlotte Roach, Brittany Watts, Monika Vilardo, Stephanie Hund, Megan Kalpakoff
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology
Tumor heterogeneity may impact immunohistochemical (IHC) interpretation, thus potentially affecting decision making by treating oncologists for cancer patient management. Programmed cell death ligand-1 (PD-L1) IHC 22C3 pharmDx is a companion diagnost
Autor:
Charlotte Roach, Myung-Ju Ahn, Amita Patnaik, Matthew D. Hellmann, Naiyer A. Rizvi, Enriqueta Felip, Rina Hui, Jin Zhang, Leena Gandhi, Edward B. Garon, Jonathan W. Goldman, Leora Horn, Gregory M. Lubiniecki, Joseph Paul Eder, Reshma A. Rangwala, Natasha B. Leighl, Enric Carcereny, Kenneth Emancipator
Publikováno v:
Annals of Oncology. 28:874-881
Background Pembrolizumab improved survival as first- and second-line therapy compared with chemotherapy in patients with highly programmed death ligand 1 (PD-L1) expressing advanced non-small cell lung cancer (NSCLC). We report the long-term safety a
Autor:
Reshma A. Rangwala, Joseph Paul Eder, Myung-Ju Ahn, Jared Lunceford, Jonathan W. Goldman, Gregory M. Lubiniecki, Jean-Charles Soria, Enriqueta Felip, Leena Gandhi, Enric Carcereny, Matthew D. Hellmann, Charlotte Roach, Ruth Z. Rutledge, Ani Sarkis Balmanoukian, Amita Patnaik, Jong-Seok Lee, Marisa Dolled-Filhart, Naiyer A. Rizvi, Omid Hamid, Kenneth Emancipator, Edward B. Garon, Jin Zhang, Natasha B. Leighl, Rina Hui, Matthew A. Gubens, Leora Horn, Charu Aggarwal
Publikováno v:
New England Journal of Medicine. 372:2018-2028
BackgroundWe assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non–small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression leve
Autor:
Adil Daud, Richard W. Joseph, Xiaoyun Nicole Li, Marisa Dolled-Filhart, Amita Patnaik, Grant Toland, Roxana S. Dronca, Wen-Jen Hwu, Charlotte Roach, Tara C. Gangadhar, Caroline Robert, Omid Hamid, Richard F. Kefford, Antoni Ribas, S. Peter Kang, Scot Ebbinghaus, Peter Hersey, Hassane M. Zarour, Anthony M. Joshua, Jared Lunceford, F. Stephen Hodi, Jedd D. Wolchok, Kenneth Emancipator, Jeffrey S. Weber
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 34, iss 34
Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti–programmed death 1 (PD-1). This study explored the relationship between anti–PD-1 activity and PD-L1 expre
Autor:
Gary Ponto, Kenneth Emancipator, Malinka Jansson, Gregory M. Lubiniecki, Marisa Dolled-Filhart, Dave Stanforth, Grant Toland, Charlotte Roach
Publikováno v:
Archives of pathologylaboratory medicine. 140(11)
Context.—Programmed death ligand-1 (PD-L1) expression by tumors may enable them to avoid immunosurveillance.Objective.—To develop a PD-L1 immunohistochemical assay using the 22C3 anti–PD-L1 murine monoclonal antibody on the Dako platform as a p
Autor:
Charlotte Roach, Ellie Corigliano, Nancy Zhang, Karina Kulangara, Kenneth Emancipator, Gary Ponto, Grant Toland, Marisa Dolled-Filhart, Malinka Jansson, Dave Stanforth
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology
A companion diagnostic assay was codeveloped by Dako for pembrolizumab non-small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This automated IHC assay has been analytically verified and validated using Da
Autor:
Dave Stanforth, Karina Kulangara, Debra Hanks, Charlotte Roach, Supriya Shah, Stephanie Waldroup, Lindsay Peltz, Jonathan Juco, Kenneth Emancipator
Publikováno v:
Journal of Clinical Oncology. 35:e14589-e14589
e14589 Background: Developing clinically relevant and highly reproducible scoring methods for PD-L1 to identify patients who will respond effectively to anti-PD-1 therapy is key in the development of companion or complementary diagnostic assays. Meth
Autor:
Grant Toland, Malinka Jansson, Gary Ponto, Scot Ebbinghaus, Charlotte Roach, Kenneth Emancipator, Marisa Dolled-Filhart
Publikováno v:
Journal of Clinical Oncology. 34:9571-9571
9571Background: PD-L1 expression on tumors contributes to tumor escape from immune surveillance. In order to determine whether PD-L1 might be useful to identify those patients (pts) with melanoma m...